reports
Herantis Pharma to present HER-096 Phase 1b data at International Conf...
Herantis Pharma to present HER-096 Phase 1b data at International Conference on Alzheimer’s & Parkinson’s Diseases Espoo, Finland, March 16, 2026: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, announces that its Chief Scientific Officer, Henri Huttunen, will be delivering an oral presentation at the 20th International Conference on Alzheimer’s & Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026), held in Denmark from 17-21 March, on data from Herantis’s Phase 1b trial of HER...
Herantis Pharma releases 2H and FY 2025 report today
Herantis Pharma releases 2H and FY 2025 report today Herantis Pharma Plc | Company Release | March 5, 2026 at 08:00:00 EET Espoo, Finland, March 5, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the Company’s 2H and FY 2025 report. The full report is attached to this release and is also available on the Company’s website: . Commenting on the results, Antti Vuolanto, CEO of Herantis Pharma, said: “2025 was a year of significant progress for Herantis Pharma, highlighted by ...
Inside information: Herantis Pharma selected for Horizon 2025 grant of...
Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096 Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparations Espoo, Finland, 19 February 2026: Herantis Pharma Plc (“Herantis”), a clinical-stage biotech company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces that it is leading a consortium that has been selected for, pending final negotiation, an EUR 8.0 million grant from the Horizon ...
Herantis Pharma - Phase 1b biomarker data show clear evidence of biolo...
Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Herantis Pharma Plc – Company release Inside information: Herantis Pharma – Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease Biomarker data show that HER-096 modulates Parkinson’s disease-relevant pathways, consistent with preclinical data, and supporting further clinical developmentHER-096 exposure was associated with changes across key disease-related pathways, including proteostasis, mitochondr...
Herantis Pharma announces successful completion of six-month GLP toxic...
Herantis Pharma announces successful completion of six-month GLP toxicology study of HER-096 Key step achieved in advancing HER-096 towards Phase 2 efficacy trial Espoo, Finland, 26 November 2025: Herantis Pharma Plc (“Herantis”), a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, today announces the successful completion of a six-month preclinical Good Laboratory Practice (GLP) toxicology study for its lead clinical asset, HER-096. The study demonstrated a favorable safety and tolerability profile, well aligned with the previou...
Herantis Pharma presents positive topline data for HER-096 in Phase 1b...
Herantis Pharma presents positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease Herantis Pharma announces positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease Trial meets all primary and secondary endpoints establishing a strong foundation to Phase 2 The clinical trial demonstrated that both repeated 200 mg and 300 mg doses of HER-096 are generally safe and well tolerated in Parkinson’s disease (PD) patients.Results from the clinical trial demonstrated a pharmacokinetic profile consistent with predictions...
Herantis Pharma releases 1H 2025 report today
Herantis Pharma releases 1H 2025 report today Espoo, Finland, 21 August 2025: Herantis Pharma Plc ("Herantis"), a clinical-stage company developing disease-modifying therapies to stop Parkinson’s disease, releases today the Company’s 1H 2025 report. The full report is available at the Company’s website: . Antti Vuolanto, CEO of Herantis, said: “We made significant clinical progress in the first half of 2025, advancing HER-096 through the Phase 1b study which is now approaching completion on schedule, a key milestone. We reported encouraging pharmacokinetic data from Part 1 of the study in ...
Last patient visit completed on schedule in Phase 1b clinical trial of...
Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300 mg doses of HER-096 or placebo twice weekly over a four-week periodPrimary objective is to assess the safety, tolerability and pharmacokinetics of repeated subcutaneous doses of HER-096; the trial will also evaluate selected biomarkers, and aims to identify novel treatment response biomarkers and monitor symptoms associated with Parkinson’s diseaseTopline Phase 1b...
First patients dosed in final cohort of Phase 1b clinical trial of HER...
First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease Herantis Pharma Plc – Press release First patients dosed in final cohort of Phase 1b clinical trial of HER-096 for Parkinson’s disease HER-096 is a first-in-class agent in development for the treatment of Parkinson’s disease with disease modifying potential and convenient subcutaneous administrationSuccessful completion of the first patient cohort in Part 2 of the trial and approval to proceed from the Data and Safety Monitoring BoardPrimary objective is to assess the safety, tolerability ...
Herantis Pharma Oyj: 1 director
A director at Herantis Pharma Oyj sold 411,000 shares at 1.500EUR and the significance rating of the trade was 96/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
- Adam Karlsson
- Adam Karlsson
- Adam Karlsson
- Rickard Anderkrans
- Viktor Sundberg
PHO PHOTOCURE ASA
ELOS B ELOS MEDTECH AB
HNSA HANSA BIOPHARMA AB
EGTX EGETIS THERAPEUTICS AB
HRTIS HERANTIS PHARMA OYJ
PROB PROBI AB
TRVX TARGOVAX AS
BONEX BONESUPPORT HOLDING AB
ARJO B ARJO B
PCIB PCI BIOTECH HOLDING ASA
ULTI ULTIMOVACS
IVACC INTERVACC AB
QLINEA Q LINEA AB
VACC VACCIBODY AS
SYNACT SYNACT PHARMA
CLNK B CELLINK AB
NANEXA NANEXA AB
- Adam Karlsson
- Rickard Anderkrans
- Viktor Sundberg
- Adam Karlsson
- Rickard Anderkrans
- Viktor Sundberg
- Adam Karlsson
- Rickard Anderkrans
- Viktor Sundberg
- Adam Karlsson
- Rickard Anderkrans
- Viktor Sundberg
- Adam Karlsson
- Rickard Anderkrans
- Viktor Sundberg
- Adam Karlsson
- Rickard Anderkrans
- Viktor Sundberg
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.